Cargando…
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell compartment, with different roles in both endocrine and nervous system. Most NETs have gastroentero-pancreatic (GEP) origin, arising in the foregut, midgut, or hindgut. The 2010 WHO classificati...
Autores principales: | De Divitiis, C., von Arx, C., Grimaldi, A. M., Cicala, D., Tatangelo, F., Arcella, A., Romano, G. M., Simeone, E., Iaffaioli, R. V., Ascierto, P. A., Tafuto, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855772/ https://www.ncbi.nlm.nih.gov/pubmed/27142424 http://dx.doi.org/10.1186/s12967-016-0857-1 |
Ejemplares similares
-
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019) -
A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
por: De Divitiis, Chiara, et al.
Publicado: (2015) -
Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
por: Tena, Isabel, et al.
Publicado: (2018) -
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012) -
Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
por: Capozzi, Monica, et al.
Publicado: (2019)